Literature DB >> 6601147

The fate of interleukin-2 after in vivo administration.

J H Donohue, S A Rosenberg.   

Abstract

Interleukin 2 (IL 2) activity was measured in the serum of mice, using a bioassay, following various methods of IL 2 administration. IL 2 has a serum half-life of 3.7 min +/- 0.8 min (mean +/- SD) in mice after i.v. injection, and a serum IL 2 titer of 2 units/ml could be sustained for less than 30 min after injection of highly concentrated IL 2 solutions. Intraperitoneal (i.p.) and subcutaneous (s.c.) injection of similar amounts of IL 2 prolonged the duration of serum IL 2 activity at greater than 2 units/ml for 2 and 6 hr, respectively. Administration of IL 2 in a gelatin base was capable of sustaining serum IL 2 levels at greater than 2 units/ml for up to 16 hr. The reason for the short in vivo half-life of i.v. injected IL 2 was studied. No inhibitors of IL 2 could be detected in our cell growth assay of IL 2 activity. Exposure of IL 2 to mouse blood or serum had no impact on IL 2 titers. To evaluate the possibility that IL 2 was binding to lymphoid cells in vivo, the fate of IL 2 was studied in nude mice, in mice 4 days after 1000 rads total body irradiation, and in splenectomized mice. The serum half-life in these modified mice was identical to that in normal mice. The kidney appeared to be the main site of IL 2 clearance. The rates of IL 2 disappearance in mice rose from a control T 1/2 of 2.5 to 3.5 min in sham-operated animals to up to 84 min in mice with ligated renal pedicles. IL 2 was not excreted in an active form in the urine and ureteral ligation had only a small effect on the serum half-life of IL 2, implying probable renal tubular catabolism of filtered IL 2.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6601147

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  98 in total

1.  Noninvasive monitoring of cancer therapy induced activated T cells using [18F]FB-IL-2 PET imaging.

Authors:  S V Hartimath; O Draghiciu; S van de Wall; V Manuelli; R A J O Dierckx; H W Nijman; T Daemen; E F J de Vries
Journal:  Oncoimmunology       Date:  2016-11-18       Impact factor: 8.110

Review 2.  Interleukins. Clinical pharmacology and therapeutic use.

Authors:  W E Aulitzky; M Schuler; C Peschel; C Huber
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

3.  Co-expression of tumor antigen and interleukin-2 from an adenoviral vector augments the efficiency of therapeutic tumor vaccination.

Authors:  Benjamin Anderschou Holbech Jensen; Maria Abildgaard Steffensen; Karen Nørgaard Nielsen; Jan Pravsgaard Christensen; Allan Randrup Thomsen; Peter Johannes Holst
Journal:  Mol Ther       Date:  2014-07-15       Impact factor: 11.454

4.  IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25.

Authors:  Sven Létourneau; Ester M M van Leeuwen; Carsten Krieg; Chris Martin; Giuseppe Pantaleo; Jonathan Sprent; Charles D Surh; Onur Boyman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-19       Impact factor: 11.205

Review 5.  Local and regional immunotherapy of cancer with interleukin 2.

Authors:  J Bubeník
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

6.  IL233, A Novel IL-2 and IL-33 Hybrid Cytokine, Ameliorates Renal Injury.

Authors:  Marta E Stremska; Sheethal Jose; Vikram Sabapathy; Liping Huang; Amandeep Bajwa; Gilbert R Kinsey; Poonam R Sharma; Saleh Mohammad; Diane L Rosin; Mark D Okusa; Rahul Sharma
Journal:  J Am Soc Nephrol       Date:  2017-05-24       Impact factor: 10.121

7.  Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.

Authors:  M Hosokawa; Y Sawamura; T Morikage; F Okada; Z Y Xu; K Morikawa; K Itoh; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

8.  The in vivo functions and properties of persisting cell-stimulating factor.

Authors:  R M Crapper; I Clark-Lewis; J W Schrader
Journal:  Immunology       Date:  1984-09       Impact factor: 7.397

9.  In vivo and in vitro administration of interleukin 2-containing preparation reverses T-cell unresponsiveness in Mycobacterium bovis BCG-infected mice.

Authors:  V Colizzi
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

Review 10.  Emerging nanotechnologies for cancer immunotherapy.

Authors:  Sourabh Shukla; Nicole F Steinmetz
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.